Background/Aims: Universal screening for thyroid diseases during pregnancy is controversial. Targeted screening does not identify all women with thyroid dysfunction. Furthermore, antithyroid peroxidase antibodies (TPOAb) are suspected to be associated with an increased risk of fetal loss, premature delivery and hypothyroidism. The aim of our study was to assess the rationale behind universal screening and propose thyroxine treatment in particular cases. Methods: Between January 2008 and May 2009, 537 consecutive iodine-supplemented women with a singleton pregnancy [441 TPOAb– controls and 96 TPOAb+ women (47 nontreated and 49 treated)] were evaluated using thyroid and obstetric parameters. According to our algorithm for thyroid screening in pregnancy, if thyroid-stimulating hormone (TSH) exceeded 1 mU/l in TPOAb+ women, 50 µg of levothyroxine (L-T4) was prescribed. Results: The miscarriage rate was significantly higher in the nontreated TPOAb+ group compared with the treated group (16 vs. 0%; p = 0.02). Compared to the control group, TSH in TPOAb+ patients was higher at the first prenatal visit prior to L-T4 treatment (p < 0.01), while free thyroxine was higher than in the control group after the 20th week (p < 0.05). Conclusions: Our study supports the potential benefit of universal screening and L-T4 treatment for autoimmune thyroid disease during pregnancy. Efforts are still needed to further decrease miscarriage rates.

Keywords:
Thyroid peroxidase antibodies, Universal screening, Miscarriage, Pregnancy, Thyroxine treatment
1.
Glinoer D: The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997;18:404–433.
2.
Poppe K, Velkeniers B, Glinoer D: The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab 2008;4:394–405.
3.
Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O: Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002;12:63–68.
4.
Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, Cunningham FG: Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol 2005;105:239–245.
5.
Allan WC, Haddow JE, Palomaki GE, Williams JR, Mitchell ML, Hermos RJ, Faix JD, Klein RZ: Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen 2000;7:127–130.
6.
Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH: Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol 1993;81:349–353.
7.
Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O’Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ: Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999;341:549–555.
8.
Lazarus JH, Bestwick JP, Channon S, Paradice R, Maina A, Rees R, Chiusano E, John R, Guaraldo V: Antenatal thyroid screening and childhood cognitive function. N Engl J Med 2012;366:493–501.
9.
Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Alvarez-Marfany M, Davies TF: Detection of at risk pregnancy using highly sensitive assays for thyroid autoantibodies. JAMA 1990;264:1422–1425.
10.
Prummel MF, Wiersinga WM: Thyroid autoimmunity and miscarriage. Eur J Endocrinol 2004;150:751–755.
11.
Glinoer D, Riahi M, Grün JP, Kinthaert J: Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders. J Clin Endocrinol Metab 1994;79:197–204.
12.
Stagnaro-Green A: Maternal thyroid disease and preterm delivery. J Clin Endocrinol Metab 2009;94:21–25.
13.
Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A: Thyroid antibody positivity in the first trimester of pregnancy is associated with negative pregnancy outcomes. J Clin Endocrinol Metab 2011;96:E920–E924.
14.
Premawardhana LD, Parkes AB, John R, Harris B, Lazarus JH: Thyroid peroxidase antibodies in early pregnancy: utility for prediction of postpartum thyroid dysfunction and implications for screening. Thyroid 2004;14:610–615.
15.
Männistö T, Vääräsmäki M, Pouta A, Hartikainen AL, Ruokonen A, Surcel HM, Bloigu A, Järvelin MR, Suvanto E: Thyroid dysfunction and autoantibodies during pregnancy as predictive factors of pregnancy complications and maternal morbidity in later life. J Clin Endocrinol Metab 2010;95:1084–1094.
16.
Pop VJ, de Vries E, van Baar AL, Waelkens JJ, de Rooy HA, Horsten M, Donkers MM, Komproe IH, van Son MM, Vader HL: Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? J Clin Endocrinol Metab 1995;80:3561–3566.
17.
Pop VJ, Kuijpens JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, Vulsma T, Wiersinga WM, Drexhage HA, Vader HL: Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf) 1999;50:149–155.
18.
Li Y, Shan Z, Teng W, Yu X, Li Y, Fan C, Teng X, Guo R, Wang H, Li J, Chen Y, Wang W, Chawinga M, Zhang L, Yang L, Zhao Y, Hua T: Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25–30 months. Clin Endocrinol (Oxf) 2010;72:825–829.
19.
Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H: Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006;91:2587–2591.
20.
Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green A: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92:S1–S47.
21.
Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W: Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1081–1125.
22.
Vaidya B, Anthony S, Bilous M, Shields B, Drury J, Hutchison S, Bilous R: Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? J Clin Endocrinol Metab 2007;92:203–207.
23.
Horacek J, Spitalnikova S, Dlabalova B, Malirova E, Vizda J, Svilias I, Cepkova J, Mc Grath C, Maly J: Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. Eur J Endocrinol 2010;163:645–650.
24.
Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A: Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J Clin Endocrinol Metab 2010;95:1699–1707.
25.
Debiève F, Dulière S, Bernard P, Hubinont C, De Nayer P, Daumerie C: To treat or not to treat euthyroid autoimmune disorder during pregnancy. Gynecol Obstet Invest 2009;67:178–182.
26.
Glinoer D, de Nayer P, Bourdoux P, Lemone M, Robyn C, van Steirteghem A, Kinthaert J, Lejeune B: Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990;71:276–287.
27.
Iijima T, Tada H, Hidaka Y, Mitsuda N, Murata Y, Amino N: Effects of autoantibodies on the course of pregnancy and fetal growth. Obstet Gynecol 1997;90:364–369.
28.
Wilson R, Ling H, MacLean MA, Mooney J, Kinnane D, McKillop JH, Walker JJ: Thyroid antibody titer and avidity in patients with recurrent miscarriage. Fertil Steril 1999;71:568–561.
29.
Thangaratinam S, Tan A, Know E, Kilby MD, Franklyn J, Coomarasamy A: Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ 2011;342:d2616.
30.
Glinoer D: Miscarriage in women with positive anti-TPO antibodies: is thyroxine the answer? J Clin Endocrinol Metab 2006;91:2500–2502.
31.
Stricker R, Echenard M, Eberhart R, Chevailler MC, Perez V, Quinn FA, Stricker R: Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. Eur J Endocrinol 2007;157:509–514.
32.
World Health Organization: Iodine deficiency in Europe: A continuing health problem. Geneva, 2007.
33.
Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A: Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab 2010;95:E44–E48.
34.
Alexander EK: Here’s to you, baby! A step forward in support of universal screening of thyroid function during pregnancy. J Clin Endocrinol Metab 2010;95:1575–1577.
35.
Dosiou C, Sanders GD, Araki SS, Crapo LM: Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. Eur J Endocrinol 2008;158:841–851.
36.
Haddow JE, McClain MR, Palomaki GE, Kloza EM, Williams J: Screening for thyroid disorders during pregnancy: results of a survey in Maine. Am J Obstet Gynecol 2006;194:471–474.
37.
Vaidya B, Hubalewska-Dydejczyk A, Laurberg P, Negro R, Vermiglio F, Poppe K: Treatment and screening of hypothyroidism in pregnancy: results of a European survey. Eur J Endocrinol 2012;166:49–54.
38.
Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L: Levothyroxine treatment in pregnancy: indications, efficacy, and therapeutic regimen. J Thyroid Res 2011;2011:843591.
39.
Glinoer D, Spencer CA: Serum TSH determinations in pregnancy: how, when and why? Nat Rev Endocrinol 2010;6:526–529.
40.
La’ulu SL, Roberts WL: Ethnic differences in first-trimester thyroid reference intervals. Clin Chem 2011;57:913–915.
41.
Bussen S, Steck T: Thyroid autoantibodies in euthyroid non-pregnant women with recurrent spontaneous abortions. Hum Reprod 1995;10:2938–2940.
42.
Bagis T, Gokcel A, Saygili ES: Autoimmune thyroid disease in pregnancy and the postpartum period: relationship to spontaneous abortion. Thyroid 2001;11:1049–1053.
43.
Glinoer D, Soto MF, Bourdoux P, Lejeune B, Delange F, Lemone M, Kinthaert J, Robijn C, Grun JP, de Nayer P: Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab 1991;73:421–427.
44.
Lejeune B, Grun JP, de Nayer P, Servais G, Glinoer D: Antithyroid antibodies underlying thyroid abnormalities and miscarriage or pregnancy induced hypertension. Br J Obstet Gynaecol 1993;100:669–672.
45.
Pratt D, Novotny M, Kaberlein G, Dudkiewicz A, Gleicher N: Antithyroid antibodies and the association with non-organ-specific antibodies in recurrent pregnancy loss. Am J Obstet Gynecol 1993;168:837–841.
46.
Muller AF, Verhoeff A, Mantel MJ, Berghout A: Thyroid autoimmunity and abortion: a prospective study in women undergoing in vitro fertilization. Fertil Steril 1999;71:30–34.
47.
Rushworth FH, Backos M, Rai R, Chilcott IT, Baxter N, Regan L: Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies. Hum Reprod 2000;15:1637–1639.
48.
Poppe K, Glinoer D, Tournaye H, Devroey P, van Steirteghem A, Kaufman L, Velkeniers B: Assisted reproduction and thyroid autoimmunity: an unfortunate combination? J Clin Endocrinol Metab 2003;88:4149–4152.
49.
Poppe K, Glinoer D, Tournaye H, Schiettecatte J, Devroey P, van Steirteghem A, Haentjens P, Velkeniers B: Impact of ovarian hyperstimulation on thyroid function in women with and without thyroid autoimmunity. J Clin Endocrinol Metab 2004;89:3808–3812.
50.
Kim CH, Chae HD, Kang BM, Chang YS: Influence of antithyroid antibodies in euthyroid women on in vitro fertilization-embryo transfer outcome. Am J Reprod Immunol 1998;40:2–8.
51.
Mecacci F, Parretti E, Cioni R, Lucchetti R, Magrini A, La Torre P, Mignosa M, Acanfora L, Mello G: Thyroid autoimmunity and its association with non-organ-specific antibodies and subclinical alterations of thyroid function in women with a history of pregnancy loss or preeclampsia. J Reprod Immunol 2000;46:39–50.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.